|
Trial Management Group |
Trial Activation |
IND.227 - A Phase II Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural Mesothelioma - was centrally activated today, October 7, 2017.
The primary objective of this study is to evaluate whether pembrolizumab, alone or given to patients receiving standard chemotherapy, improves progression-free survival in malignant pleural mesothelioma (MPM) compared to standard chemotherapy. Secondary objectives include to:
|